Early Development Asset Lead

** Titre :
** Early Development Asset Lead
** Société:
** Ipsen Biopharm Ltd
** A propos d'Ipsen:
** Ipsen est un groupe biopharmaceutique mondial de taille moyenne, spécialisé dans les médicaments transformateurs dans trois aires thérapeutiques : l'oncologie, les maladies rares et les neurosciences. Forts de près de 100 ans d'expérience en développement, avec des Hubs mondiaux aux États-Unis, en France et au Royaume-Uni, nous focalisons nos efforts là où les besoins médicaux non satisfaits sont import ants, grâce à la recherche et à l'innovation.

Nos équipes passionnées, présentes dans plus de 40 pays, se concentrent sur l'essentiel et s'efforcent chaque jour d'apporter des médicaments aux patients dans 88 pays. Nous construisons un environnement de travail qui met en avant un leadership centré sur l'humain et favorise une culture de collaboration, d'excellence et d'impact. Au sein d’Ipsen, chaque individu est encouragé à être soi-même, à grandir et à s’épanouir aux côtés du succès de l'entreprise.

Rejoignez-nous dans notre démarche vers une croissance durable, en créant un impact réel sur les patients et la société.

Pour plus d'informations, visitez notre site web à l'adresse
**** et suivez nos dernières actualités sur
** Linked In
* * et
** Instagram**.
** Description de l'emploi :
** Early Development Asset Lead  Division / Function:
Early Development and Innovation  Summary / Purpose of the Position The Early Development Asset Lead (EDAL) is a scientific and program leadership role within Ipsen's Early Development and Innovation organization, accountable for integrated development strategy and execution for one or more early-stage therapeutic assets from drug candidate nomination through first-in-human clinical trials.  The EDAL leads the Early Development Asset Team (EDT), a cross-functional matrix team spanning clinical, regulatory, CMC, translational, clinical pharmacology, nonclinical safety, and biomarkers, ensuring that each program advances with scientific rigor, strategic clarity, and accountability to portfolio decisions.

The EDAL maintains alignment with Therapeutic Area strategy to ensure EDT plans support agreed portfolio priorities, and serves as the scientific champion for assigned programs, articulating project goals, scientific rationale, and clinical line of sight internally and externally. Depending on pipeline needs, the EDAL may represent Early Development in due diligence as the ED lead within a multidisciplinary global team.

Main Responsibilities / Job Expectations Program Leadership and Strategy
• Leads one or more Early Development Asset Teams.
• Owns integrated program strategy across preclinical, translational, clinical, diagnostic, and regulatory activities.
• Develops and maintains integrated asset strategy, including target product profile, indication strategy, key development options, competitive context, and evidence required for decision-making.
• Ensures Early Development plans deliver against agreed Therapeutic Area strategy and portfolio priorities, with clear evidence-based rationale for stage-gate investment decisions.

Cross-Functional Planning and Execution
• Integrates input from critical functions and research teams to develop plans that balance scientific risk, timelines, cost, and clinical proof-of-concept potential.
• Ensures adequate resources to deliver approved plans, proactively identifies risks, and leads mitigation strategies.

Governance and Decision-Making
• Presents plans, data, risks, options, and recommendations to governance bodies with scientific credibility, while appropriately leveraging functional expertise.

Team Leadership and Communication
• Builds high-functioning teams through clear communication of program vision, roles,…